AMPH · Amphastar Pharmaceuticals, Inc.
$23.78
+1.02% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$1B
Trailing P/E
13.9
Forward P/E
7.4
Dividend yield
—
Beta
0.92
Avg volume
0M
Employees
2K
Daily Change %
1.02%
5 Days Change
-0.60%
10 Days Change
2.26%
30 Days Change
12.83%
60 Days Change
23.08%
Month to Day Change
0.35%
Year to Day Change
-13.97%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMPH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-18
Latest call per bank · past 12 months
Barclays
Equal-Weight$23.00
-2.3% vs priceWells Fargo
Equal-Weight$20.00
-15.0% vs priceBank of America
Underperform$20.00
-15.0% vs priceJefferies
Hold$22.00
-6.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-18 | Barclays | Maintains | Equal-Weight | $20.00 → $23.00 |
| 2026-08-07 | Piper Sandler | Maintains | Neutral | $21.00 → $20.00 |
| 2026-08-07 | Wells Fargo | Maintains | Equal-Weight | $19.00 → $20.00 |
| 2026-06-29 | Bank of America | Downgrade | Neutral → Underperform | $25.00 → $20.00 |
| 2026-06-03 | Barclays | Maintains | Equal-Weight | $23.00 → $20.00 |
| 2026-05-14 | Wells Fargo | Downgrade | Overweight → Equal-Weight | $30.00 → $19.00 |
| 2026-05-11 | Piper Sandler | Reiterates | Neutral | $25.00 → $21.00 |
| 2026-05-08 | Needham | Downgrade | Buy → Hold | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 69 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 14.5% above the 50-day MA ($20.77).
- Price vs 200-day MA: Trading 5.8% above the 200-day MA ($22.47).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.07) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($16.87) and high ($29.40).
AMPH Price Chart
Loading chart for AMPH…
Fundamentals
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.